Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites

Ji Hye Kim, Ji Ho Lee, Young Min Ye, Jae Hyun Lee, Jungwon Park, Gyu Young Hur, Joo Hee Kim, Hyn Young Lee, Yoo Seob Shin, Eun Mi Yang, Hae Sim Park

Research output: Contribution to journalArticle

Abstract

Purpose: This study aims to determine the efficacy and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in elderly patients with AR. Methods: A total of 45 patients aged ≥ 60 years with HDM-induced AR who had ≥ 3 A/H ratio on skin prick test and/or ≥ 0.35 IU/L to both Dermatophagoides farinae and Dermatophagoides pteronyssinus by ImmunoCAP were enrolled in 4 university hospitals. To evaluate additional effects of HDM-SLIT, they were randomized to the SLIT-treated group (n = 30) or control group (n = 15). Rhinoconjunctivitis total symptom score (RTSS), rhinoscopy score, Korean rhinoconjunctivitis quality of life questionnaire, rhinitis control assessment test, asthma control test scores, and adverse reactions, were assessed at the first visit (V1) and after 1 year of treatment (V5); for immunological evaluation, serum levels of HDM-specific immunoglobulin A/IgE/IgG1/IgG4 antibodies and basophil response to HDMs were compared between V1 and V5 in both groups. Results: There were no significant differences in demographics, RTSS, skin reactivity to HDMs, or serum total/specific IgE levels to HDMs (P > 0.05, respectively) between the 2 groups. Nasal symptom score and RTSS decreased significantly at year 1 in the 2 groups (P < 0.05). There were no significant differences in percent decrease in nasal symptom score and RTSS at year 1 between the 2 groups (P > 0.05); however, rhinoscopic nasal symptom score decreased significantly in the SLIT-treated group (P < 0.05). Immunological studies showed that serum specific IgA levels (not specific IgE/IgG) and CD203c expression on basophils decreased significantly at V5 in the SLIT-treated group (P = 0.011 and P = 0.001, respectively), not in the control group. The control group required more medications compared to the treatment group, but there were no differences in adverse reactions. Conclusions: It is suggested that HDM-SLIT for 1 year could induce symptom improvement and may induce immunomodulation in elderly rhinitis patients.

Original languageEnglish
Pages (from-to)675-685
Number of pages11
JournalAllergy, Asthma and Immunology Research
Volume10
Issue number6
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Sublingual Immunotherapy
Pyroglyphidae
Rhinitis
Safety
Immunoglobulin E
Basophils
Immunoglobulin G
Nose
Immunoglobulin A
Control Groups
Serum
Dermatophagoides farinae
Dermatophagoides pteronyssinus
Immunomodulation
Skin Tests
Antibody Formation
Asthma
Quality of Life
Demography
Skin

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Kim, Ji Hye ; Lee, Ji Ho ; Ye, Young Min ; Lee, Jae Hyun ; Park, Jungwon ; Hur, Gyu Young ; Kim, Joo Hee ; Lee, Hyn Young ; Shin, Yoo Seob ; Yang, Eun Mi ; Park, Hae Sim. / Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. In: Allergy, Asthma and Immunology Research. 2018 ; Vol. 10, No. 6. pp. 675-685.
@article{89148c19f0ea4780a906717e2394d0c5,
title = "Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites",
abstract = "Purpose: This study aims to determine the efficacy and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in elderly patients with AR. Methods: A total of 45 patients aged ≥ 60 years with HDM-induced AR who had ≥ 3 A/H ratio on skin prick test and/or ≥ 0.35 IU/L to both Dermatophagoides farinae and Dermatophagoides pteronyssinus by ImmunoCAP were enrolled in 4 university hospitals. To evaluate additional effects of HDM-SLIT, they were randomized to the SLIT-treated group (n = 30) or control group (n = 15). Rhinoconjunctivitis total symptom score (RTSS), rhinoscopy score, Korean rhinoconjunctivitis quality of life questionnaire, rhinitis control assessment test, asthma control test scores, and adverse reactions, were assessed at the first visit (V1) and after 1 year of treatment (V5); for immunological evaluation, serum levels of HDM-specific immunoglobulin A/IgE/IgG1/IgG4 antibodies and basophil response to HDMs were compared between V1 and V5 in both groups. Results: There were no significant differences in demographics, RTSS, skin reactivity to HDMs, or serum total/specific IgE levels to HDMs (P > 0.05, respectively) between the 2 groups. Nasal symptom score and RTSS decreased significantly at year 1 in the 2 groups (P < 0.05). There were no significant differences in percent decrease in nasal symptom score and RTSS at year 1 between the 2 groups (P > 0.05); however, rhinoscopic nasal symptom score decreased significantly in the SLIT-treated group (P < 0.05). Immunological studies showed that serum specific IgA levels (not specific IgE/IgG) and CD203c expression on basophils decreased significantly at V5 in the SLIT-treated group (P = 0.011 and P = 0.001, respectively), not in the control group. The control group required more medications compared to the treatment group, but there were no differences in adverse reactions. Conclusions: It is suggested that HDM-SLIT for 1 year could induce symptom improvement and may induce immunomodulation in elderly rhinitis patients.",
author = "Kim, {Ji Hye} and Lee, {Ji Ho} and Ye, {Young Min} and Lee, {Jae Hyun} and Jungwon Park and Hur, {Gyu Young} and Kim, {Joo Hee} and Lee, {Hyn Young} and Shin, {Yoo Seob} and Yang, {Eun Mi} and Park, {Hae Sim}",
year = "2018",
month = "11",
day = "1",
doi = "10.4168/aair.2018.10.6.675",
language = "English",
volume = "10",
pages = "675--685",
journal = "Allergy, Asthma and Immunology Research",
issn = "2092-7355",
publisher = "Korean Academy of Asthma, Allergy and Clinical Immunology",
number = "6",

}

Kim, JH, Lee, JH, Ye, YM, Lee, JH, Park, J, Hur, GY, Kim, JH, Lee, HY, Shin, YS, Yang, EM & Park, HS 2018, 'Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites', Allergy, Asthma and Immunology Research, vol. 10, no. 6, pp. 675-685. https://doi.org/10.4168/aair.2018.10.6.675

Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. / Kim, Ji Hye; Lee, Ji Ho; Ye, Young Min; Lee, Jae Hyun; Park, Jungwon; Hur, Gyu Young; Kim, Joo Hee; Lee, Hyn Young; Shin, Yoo Seob; Yang, Eun Mi; Park, Hae Sim.

In: Allergy, Asthma and Immunology Research, Vol. 10, No. 6, 01.11.2018, p. 675-685.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites

AU - Kim, Ji Hye

AU - Lee, Ji Ho

AU - Ye, Young Min

AU - Lee, Jae Hyun

AU - Park, Jungwon

AU - Hur, Gyu Young

AU - Kim, Joo Hee

AU - Lee, Hyn Young

AU - Shin, Yoo Seob

AU - Yang, Eun Mi

AU - Park, Hae Sim

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: This study aims to determine the efficacy and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in elderly patients with AR. Methods: A total of 45 patients aged ≥ 60 years with HDM-induced AR who had ≥ 3 A/H ratio on skin prick test and/or ≥ 0.35 IU/L to both Dermatophagoides farinae and Dermatophagoides pteronyssinus by ImmunoCAP were enrolled in 4 university hospitals. To evaluate additional effects of HDM-SLIT, they were randomized to the SLIT-treated group (n = 30) or control group (n = 15). Rhinoconjunctivitis total symptom score (RTSS), rhinoscopy score, Korean rhinoconjunctivitis quality of life questionnaire, rhinitis control assessment test, asthma control test scores, and adverse reactions, were assessed at the first visit (V1) and after 1 year of treatment (V5); for immunological evaluation, serum levels of HDM-specific immunoglobulin A/IgE/IgG1/IgG4 antibodies and basophil response to HDMs were compared between V1 and V5 in both groups. Results: There were no significant differences in demographics, RTSS, skin reactivity to HDMs, or serum total/specific IgE levels to HDMs (P > 0.05, respectively) between the 2 groups. Nasal symptom score and RTSS decreased significantly at year 1 in the 2 groups (P < 0.05). There were no significant differences in percent decrease in nasal symptom score and RTSS at year 1 between the 2 groups (P > 0.05); however, rhinoscopic nasal symptom score decreased significantly in the SLIT-treated group (P < 0.05). Immunological studies showed that serum specific IgA levels (not specific IgE/IgG) and CD203c expression on basophils decreased significantly at V5 in the SLIT-treated group (P = 0.011 and P = 0.001, respectively), not in the control group. The control group required more medications compared to the treatment group, but there were no differences in adverse reactions. Conclusions: It is suggested that HDM-SLIT for 1 year could induce symptom improvement and may induce immunomodulation in elderly rhinitis patients.

AB - Purpose: This study aims to determine the efficacy and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in elderly patients with AR. Methods: A total of 45 patients aged ≥ 60 years with HDM-induced AR who had ≥ 3 A/H ratio on skin prick test and/or ≥ 0.35 IU/L to both Dermatophagoides farinae and Dermatophagoides pteronyssinus by ImmunoCAP were enrolled in 4 university hospitals. To evaluate additional effects of HDM-SLIT, they were randomized to the SLIT-treated group (n = 30) or control group (n = 15). Rhinoconjunctivitis total symptom score (RTSS), rhinoscopy score, Korean rhinoconjunctivitis quality of life questionnaire, rhinitis control assessment test, asthma control test scores, and adverse reactions, were assessed at the first visit (V1) and after 1 year of treatment (V5); for immunological evaluation, serum levels of HDM-specific immunoglobulin A/IgE/IgG1/IgG4 antibodies and basophil response to HDMs were compared between V1 and V5 in both groups. Results: There were no significant differences in demographics, RTSS, skin reactivity to HDMs, or serum total/specific IgE levels to HDMs (P > 0.05, respectively) between the 2 groups. Nasal symptom score and RTSS decreased significantly at year 1 in the 2 groups (P < 0.05). There were no significant differences in percent decrease in nasal symptom score and RTSS at year 1 between the 2 groups (P > 0.05); however, rhinoscopic nasal symptom score decreased significantly in the SLIT-treated group (P < 0.05). Immunological studies showed that serum specific IgA levels (not specific IgE/IgG) and CD203c expression on basophils decreased significantly at V5 in the SLIT-treated group (P = 0.011 and P = 0.001, respectively), not in the control group. The control group required more medications compared to the treatment group, but there were no differences in adverse reactions. Conclusions: It is suggested that HDM-SLIT for 1 year could induce symptom improvement and may induce immunomodulation in elderly rhinitis patients.

UR - http://www.scopus.com/inward/record.url?scp=85054953961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054953961&partnerID=8YFLogxK

U2 - 10.4168/aair.2018.10.6.675

DO - 10.4168/aair.2018.10.6.675

M3 - Article

VL - 10

SP - 675

EP - 685

JO - Allergy, Asthma and Immunology Research

JF - Allergy, Asthma and Immunology Research

SN - 2092-7355

IS - 6

ER -